

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

May 2, 2014

Commission File Number 001-35203

---

**THERATECHNOLOGIES INC.**

(Translation of registrant's name into English)

---

2310 Alfred-Nobel Boulevard  
Montréal, Québec, Canada  
H4S 2B4

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes       No

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes       No

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_.

---

---

**THERATECHNOLOGIES INC.**

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
99.1	Press Release Dated May 1, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THERATECHNOLOGIES INC.

By: /s/ Jocelyn Lafond

Name: Jocelyn Lafond

Title: Vice President, Legal Affairs

Date: May 2, 2014



**THERATECHNOLOGIES REGAINS RIGHTS TO EGRIFTA®  
(tesamorelin for injection) IN THE UNITED STATES**

**CLOSING OF TRANSACTION MARKS NEW ERA FOR THERATECHNOLOGIES**

**Montreal, Canada – May 1, 2014** - Theratechnologies Inc. (TSX: TH) today announced the closing of the transaction with EMD Serono, Inc. in which Theratechnologies regained all rights to *EGRIFTA*® (tesamorelin for injection) in the United States, including its commercialisation rights.

“We now have full control over Egrifta in the United States. Over the last few months, we have worked to prepare for this crucial milestone in our Company’s history. Our team, along with our collaborator in the U.S., inVentiv Health are eager and ready for this new challenge.”, said Mr. Luc Tanguay, President and CEO, Theratechnologies Inc.

As announced last December, Theratechnologies and EMD Serono entered into a termination and transfer agreement pursuant to which EMD Serono agreed to terminate its collaboration and licensing agreement with Theratechnologies in consideration of an early termination fee of USD 20 million payable over a five-year period starting on the first anniversary of the closing date. Starting in 2016, under the termination and transfer agreement, Theratechnologies will also pay an undisclosed, increasing royalty based on annual net sales. Royalties will be paid until a cumulative aggregate amount is reached or until January 1, 2024, the first of these events to occur. National Bank Financial acted as the exclusive financial advisor to Theratechnologies for this transaction.

“This transaction represents a springboard for the future of our company. From a research-oriented biotechnology company, Theratechnologies is entering a new phase that will see it become a truly integrated pharmaceutical company,” said Mrs. Dawn Svoronos, Chair of the Board, Theratechnologies.

**About Theratechnologies**

Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and improved quality of life. Further information about Theratechnologies is available on the Company’s website at [www.theratech.com](http://www.theratech.com), on SEDAR at [www.sedar.com](http://www.sedar.com) and on the SEC’s website at [www.sec.gov](http://www.sec.gov).

-30-

**Information:**

Denis Boucher  
NATIONAL Public Relations  
514-843-2393